Showing posts from August, 2020

Thank You 2020 Sponsors and Exhibitors!

  The ISEH Annual Meeting looked a bit different this year. We celebrated the 2020 Virtual Scientific Meeting with our exciting program including career and technology sessions, as well as talks and poster presentations from trainees, new investigators and leaders in the field. On behalf of the ISEH Board of Directors, volunteers, and staff, we'd like to thank our 2020 sponsors and exhibitors, seen below. We hope to see you all in New York in 2021! This program is supported by an independent medical education grant by Celgene Corporation. THANK YOU TO OUR 2020 GOLD SPONSOR THANK YOU TO OUR 2020 SILVER SPONSORS THANK YOU TO OUR 2020 BRONZE SPONSORS THANK YOU TO OUR SUPPORTERS Funding for this conference was made possible (in part) by 1R13HL154589-01 from the National Heart, Lung and Blood Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the NIH; nor does mention by trade

2020 Award Winner Spotlight Series: Part IV

This week on Simply Blood we are wrapping up our 2020 Interview Spotlight Series. In Part IV we are featuring the 2020 ISEH Donald Metcalf Award Winner: Harvey Lodish, MD . Here, he answers questions about his life, work, mentorship, and more. Have additional questions for Dr. Lodish? Don't miss his opening Keynote session at this year’s Virtual Scientific Meeting !

Exploring Experimental Hematology: July 2020 (Volume 87)

In this issue of Simply Blood, we are highlighting and deconstructing one of the journal’s latest manuscripts by first author Darlene A. Monlish. In a recent study in the laboratory of Dr. Laura Schuettpelz (Washington University School of Medicine), Monlish et al described heterodimer-specific effects of TLR2 signaling on premalignant hematopoietic stem and progenitor cells (HSPCs) in a mouse model of myelodysplastic syndromes (MDS). ( Monlish et al., 2020 ). TLR2 expression is increased on the HSPCs of patients with MDS, however its role in MDS pathogenesis is not clear. Notably, TLR2 heterodimerizes with TLR1 or TLR6, and while high TLR2 is associated with lower-risk disease, high TLR6, but not TLR1, correlates with higher-risk disease. This raises the possibility of heterodimer-specific effects of TLR2 signaling in MDS. Indeed, the authors found that chronic stimulation of TLR2/6 (but not TLR1/2) signaling accelerated leukemic transformation in a NUP98-HOXD13 (NHD13) mouse model of